After a five-month hold put a damper on uniQure’s hemophilia B gene therapy program, things are finally looking up as a positive pivotal readout puts the company and partner CSL Behring on track to file for approval in the first half of next year — and analysts spy blockbuster potential.…
Radius Health saw shares tank on Wednesday after reporting two Phase III study results, one for an osteoporosis patch treatment that failed and one for a breast cancer therapy showing lower efficacy…
Sandoz has issued a recall of one lot of its enoxaparin sodium injection, 40 mg/.4 mL single-dose syringes after exposure to high temperatures may have impacted product effectiveness. The lot, dubbed…
After chalking up half a dozen tuck-in acquisitions throughout its fiscal year 2021—which ended Sept. 30—BD seems poised to outdo itself in 2022. Its first two tuck-in acquisitions of fiscal year 2022…
Nanomedicine shrinks vascular lesions in mice and could pave path to new treatments
klahucik
Thu, 12/09/2021 – 12:34
Unlike some of its Big Pharma peers, Novartis has not been at the forefront of creating new vaccines and treatments against COVID. Now, however, it’s taking its massive R&D budget and targeting not…
After the U.S. House of Representatives overwhelmingly passed a bill that would grant $500 million to ALS research, three organizations called on the Senate to swiftly follow suit. The muscle-wasting…
Selecting the right target to kill off cancer cells while sparing healthy cells has been challenging for companies developing off-the-shelf cell therapies. Now, Senti Bio has promising early data on…
Over a year after doling out an emergency use authorization for a handful of Philips’ IntelliVue patient monitoring devices, the FDA is doubling down on the regulatory nod.
After 3.5 years and oversight of approvals in the U.S. and Europe for its rare liver disease drug, Bylvay, Pat Horn is out as chief medical officer of Albireo Pharma. He notified the Boston biopharma…
